强生公司的迹象处理公司为中国乙肝药

StephenW

J&J signs deal with Chinese company for hepatitis B drug                            By Bill Berkrot            
           

• 
  

            
                                


<span class="articleLocation">Johnson & Johnson on Thursday said it licensed rights from a Chinese drugmaker to drugs that spur the immune system to help fight diseases, which it hopes will become a key part of a cure for chronic hepatitis B.

The deal, with a unit of Sino Biopharmaceutical Ltd that focuses on treatments for liver diseases, gives J&J exclusive rights to develop, manufacture and sell the medicines outside China.

Unlike new hepatitis C drugs that boast extremely high cure rates and short treatment durations, current medicines for the hepatitis B virus (HBV) can hold it in check but must be taken for life. If untreated, the virus, which is spread by contact with infected bodily fluids, can be fatal and is a leading cause of liver cancer.

Hepatitis B has been difficult to cure because antiviral medicines that block replication of the virus have proved insufficient at clearing it from the blood.

J&J and other researchers believe an assault by components of the immune system will be needed as part of a cure.

               
The deal with Sino's Chia Tai Tiaqing Pharmaceutical unit includes an immune-stimulating agent that could potentially be combined with antiviral drugs J&J acquired when it purchased Novira Therapeutics in November.

"With the Novira acquisition we have the lead direct antiviral in the world for HBV," Lawrence Blatt, head of infectious diseases and vaccines for J&J's Janssen pharmaceutical unit, said in an interview.

"If we can in the same time we're giving direct antivirals and blocking (virus) replication, activate the immune system and wake it up, maybe we can cause patients to clear HBV," Blatt said.

               
Hepatitis B is an enormous market and far more prevalent than hepatitis C, particularly in Asia, with more than 350 million sufferers worldwide compared with about 130 million with hepatitis C.

"Our aim is to develop a cure for hepatitis B by building the best internal and external pipeline of promising, complementary solutions, and advancing them into the clinic as rapidly as possible," Janssen research chief William Hait said in a statement.

               
Several companies are working on hepatitis B treatments, including Arrowhead Research Corp, Tekmira Pharmaceuticals, and privately held OnCore Biopharma, which is led by the scientists who discovered Gilead Sciences' market-leading hepatitis C treatment.

Blatt said hepatitis B will be much tougher to crack than hepatitis C. "It's going to get cracked," he said. "There's enough critical mass right now."



(Reporting by Bill Berkrot; Editing by Cynthia Osterman)

StephenW

强生公司的迹象处理公司为中国乙肝药
比尔Berkrot

强生公司周四表示，行货从中国的制药商，以药物刺激免疫系统，帮助抵抗疾病，它希望将成为治疗慢性乙肝的关键部分权利

这笔交易，与中国生物制药有限公司的子公司，专注于肝病治疗方法，给出了强生的独家开发权，生产和销售中国以外的药品。

不同于新的丙型肝炎药物，拥有非常高的治愈率，短治疗时间，目前用药为乙型肝炎病毒（HBV）可以保持在检查，但必须终身服用。如果不进行治疗，病毒，它是通过传播与受感染的体液接触，可能是致命的，是肝癌的一个主要原因。

乙型肝炎一直难以治愈，因为阻断病毒复制的抗病毒药物已被证明不足以在从血液清除它。

强生公司和其他研究人员认为的攻击被免疫系统的组成部分，将需要作为固化的一部分。

与中正大Tiaqing药业单元此次交易包括免疫刺激剂有可能被用抗病毒药物强生公司收购合并时，它在十一月购买Novira治疗。

“随着Novira收购，我们有铅直接抗病毒在世界上乙肝病毒，”劳伦斯·布拉特，传染病和疫苗强生公司的杨森制药部负责人在接受采访时说。

“如果我们能在同一时间我们给直接抗病毒药物和阻断（病毒）的复制，激活免疫系统，并唤醒它，也许我们可以导致患者清除HBV，”布拉特说。

乙型肝炎是一个巨大的市场，远远超过丙型肝炎较为普遍，特别是在亚洲，在全球拥有超过3.5亿患者约有1.3亿丙肝相比，

“我们的目标是通过建立有前途的，互补的解决方案的最好的内部和外部的管道，并推动他们到诊所尽快开发出治疗乙肝”，扬森研究主管威廉Hait在一份声明中说。

有几家公司正在对乙型肝炎的治疗，包括箭头研究公司，Tekmira制药和私人持有OnCore生物医药，这是领导的谁发现吉利德科学公司市场领先的丙型肝炎治疗的科学家。

布拉特说，乙肝也将更加激烈破解比丙型肝炎。“它会得到破解，”他说。 “有足够的临界质量现在。”

（由比尔Berkrot报告;编辑由辛西娅·奥斯特曼）

zgct

中国高层应该深刻扶持支持杨森制药！加快好药上市，子民拥戴

MP4

正大天晴制药

StephenW

回复 MP4 的帖子

你可以调查什么药？

MP4

StephenW 发表于 2016-1-8 16:15
回复 MP4 的帖子

你可以调查什么药？

我也想知道，过些天再看看天晴有没公告
天晴有长效干扰素的项目